Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H0N5
UPID:
PHS2_HUMAN
Alternative names:
4-alpha-hydroxy-tetrahydropterin dehydratase 2; DcoH-like protein DCoHm; Dimerization cofactor of hepatocyte nuclear factor 1 from muscle; HNF-1-alpha dimerization cofactor
Alternative UPACC:
Q9H0N5; Q8TD40
Background:
Pterin-4-alpha-carbinolamine dehydratase 2, also known as 4-alpha-hydroxy-tetrahydropterin dehydratase 2, plays a crucial role in tetrahydrobiopterin biosynthesis. It prevents the formation of 7-pterins and accelerates the formation of quinonoid-BH2. Additionally, it regulates the dimerization of homeodomain protein HNF-1-alpha, enhancing its transcriptional activity.
Therapeutic significance:
Understanding the role of Pterin-4-alpha-carbinolamine dehydratase 2 could open doors to potential therapeutic strategies.